About Syntimmune
Syntimmune is a Healthcare company based in New York (United States) founded in 2013, and was acquired by Alexion in September 2018. IgG-mediated autoimmune diseases are treated via Fc receptor-targeting antibodies. Syntimmune has raised $78 million across 5 funding rounds from investors including Alexion, Baxalta and Apple Tree Partners. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting. Its competitors include Moderna, BeiGene and Biogen; 3 of its 3 listed competitors have raised funding.
Company details
The company was founded in 2013 in New York, United States, within the biotechnology sector. Neonatal Fc receptor (FcRn) biology is investigated as a target for IgG-mediated autoimmune diseases. The lead program, SYNT001, consists of a biologic designed to block the FcRn-IgG interaction and is undergoing IND-enabling studies for one such disease. Two further programs addressing distinct elements of FcRn biology are under development.
- Headquarters New York, United States
- Stage Acquired
- SectorsHealthcare
- Website syntimmune.com
- Acquired by Alexion (Sep 2018)
Funding Insights of Syntimmune
Syntimmune has successfully raised a total of $78M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in June 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78M
- Total Rounds 5
- Last Round Series B — $50M
- First Round $2M
(Jun 2013)
- Investors Count 3
All 5 funding rounds of Syntimmune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2017 | $50M | Series B | – | Apple Tree Partners | – |
| Nov 2016 | $8M | Series A | – | Apple Tree Partners | |
| Mar 2016 | $10M | Series A | – | Apple Tree Partners | |
| Oct 2014 | $8M | Series A | – | Apple Tree Partners | – |
| Jun 2013 | $2M | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Syntimmune
Syntimmune has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Alexion, Baxalta and Apple Tree Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Apple Tree Partners is engaged in life sciences venture capital. | appletreepartners.com | |||
Developer of therapies for orphan diseases and other disease conditions | 2015 | baxalta.com | Chicago, United States | |
| partners.org | ||||
Therapies for rare and devastating diseases are developed by Alexion. | 1992 | alexion.com | Zurich, Switzerland |
Investor details for Syntimmune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Syntimmune
4 dated milestones of Syntimmune across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Syntimmune is founded.
- Funding First funding round of $2.0M.
- Funding Latest funding round, Series B, of $50.0M.
- Exit Acquired by Alexion.
Competitors of Syntimmune
Syntimmune has 3 listed competitors in our database, 3 of them funded. They include Moderna, BeiGene and Biogen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. |
Detailed competitors of Syntimmune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Syntimmune (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Syntimmune
Complete news archive for Syntimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syntimmune
Syntimmune was founded in 2013.
Syntimmune is headquartered in New York, United States. It is registered at New York, New York, United States.
Syntimmune is a funded company, having raised a total of $78M across 5 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Jun 2013.
The company was founded in 2013 in New York, United States, within the biotechnology sector. Neonatal Fc receptor (FcRn) biology is investigated as a target for IgG-mediated autoimmune diseases. The lead program, SYNT001, consists of a biologic designed to block the FcRn-IgG interaction and is undergoing IND-enabling studies for one such disease. Two further programs addressing distinct elements of FcRn biology are under development.
Syntimmune has 4 investors. Key investors include Alexion, Baxalta, Apple Tree Partners, and Partners HealthCare.
Yes. Syntimmune was acquired by Alexion in September 2018.